Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06285136 | Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult | unknown | Phase 2 / Phase 3 | 40 | The Second Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT04257175 | CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression | unknown | Phase 2 / Phase 3 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Nov 28, 2023 |
| NCT05313958 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children(SCCLG-M5) | unknown | Phase 2 / Phase 3 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05264883 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML | unknown | Phase 3 | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT03846362 | A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML | unknown | Phase 3 | 500 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT05311943 | Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | unknown | Phase 3 | 40 | Shenzhen Second People's HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05382390 | Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | unknown | Phase 3 | 130 | Huihan WangOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT04490707 | Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML | unknown | Phase 3 | 60 | Ge ZhengOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT03942094 | Nilotinib for First-line Newly Diagnosed CML-CP Patients | unknown | Phase 3 | 100 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04174612 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance(AMELIORATE) | unknown | Phase 3 | 172 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT04722952 | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML | unknown | Phase 3 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT04716114 | A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated(ALIVE) | unknown | Phase 3 | 315 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 2, 2021 | clinicaltrials |
| NCT03257241 | A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old(PALG-AML1/2016) | unknown | Phase 3 | 582 | Polish Adult Leukemia GroupOTHER | 2 | Oct 1, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT02899169 | Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)(APL16) | unknown | Phase 3 | 110 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03800095 | Early Palliative Care for Patients With Haematological Malignancies(CALVI) | unknown | Phase 3 | 140 | University Hospital, Clermont-FerrandOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT02381379 | Malaysia Stop Tyrosine Kinase Inhibitor Trial(MSIT) | unknown | Phase 3 | 118 | Ministry of Health, MalaysiaOTHER_GOV | 1 | Sep 14, 2020 | clinicaltrials |
| NCT02059720 | Haplo-SCT vs ASCT With or Without Decitabine in AML CR1 | unknown | Phase 3 | 212 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02272478 | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations(AML18) | unknown | Phase 2 / Phase 3 | 1,600 | Cardiff UniversityOTHER | 2 | Jan 23, 2020 | clinicaltrials |
| NCT04216771 | Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | unknown | Phase 2 / Phase 3 | 320 | Fujian Medical UniversityOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT04175587 | Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL(RIF) | unknown | Phase 3 | 109 | Peking University People's HospitalOTHER | 0 | Nov 29, 2019 | clinicaltrials |
| NCT04087967 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | unknown | Phase 3 | 162 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT04083911 | Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | unknown | Phase 3 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03665480 | The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03701217 | Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML | unknown | Phase 2 / Phase 3 | 220 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03655145 | HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation(MacHaploMud) | unknown | Phase 3 | 344 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT03642236 | Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT03515018 | Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients(HU) | unknown | Phase 3 | 60 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT03256071 | Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01226303 | Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia | unknown | Phase 3 | 300 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02979548 | Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy | unknown | Phase 3 | 116 | Dr Atul SharmaOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT01828489 | Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years(AML2012) | unknown | Phase 3 | 300 | Vastra Gotaland RegionOTHER_GOV | 9 | Jan 10, 2017 | clinicaltrials |
| NCT02985372 | Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia | unknown | Phase 3 | 30 | Chunyan JiOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01484171 | HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | unknown | Phase 3 | 50 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02171117 | Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia(IMCG-EAML) | unknown | Phase 3 | 196 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02244658 | Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia | unknown | Phase 3 | 80 | Shandong UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01800643 | Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | Phase 2 / Phase 3 | 100 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT02072811 | Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia(PALG-AML2012) | unknown | Phase 3 | 400 | dr hab. n. med. Agnieszka WierzbowskaOTHER | 1 | Feb 27, 2014 | clinicaltrials |
| NCT01400074 | Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib(RE-NICE) | unknown | Phase 3 | 100 | Seoul St. Mary's HospitalOTHER | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01809392 | Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 2 / Phase 3 | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT01766375 | the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient(IDBUCY) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 11, 2013 | clinicaltrials |
| NCT01615757 | Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation(Ara-c) | unknown | Phase 3 | 180 | All India Institute of Medical SciencesOTHER | 1 | Sep 17, 2012 | clinicaltrials |
| NCT01633099 | Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients | unknown | Phase 3 | 46 | Jianxiang WangUNKNOWN | 0 | Jul 6, 2012 | clinicaltrials |
| NCT00111345 | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | unknown | Phase 2 / Phase 3 | 550 | University Hospital MuensterOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT01414231 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a(OSHO#061) | unknown | Phase 3 | 850 | University of LeipzigOTHER | 1 | Aug 11, 2011 | clinicaltrials |
| NCT00715637 | Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study | unknown | Phase 3 | 420 | Antisoma ResearchINDUSTRY | 23 | Oct 13, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Feb 29, 2024source: clinicaltrials